Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB5O1U
|
|||
| Drug Name |
H3B-8800
|
|||
| Synonyms |
(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Chronic myelomonocytic leukaemia [ICD-11: 2A40; ICD-10: C93.1] | Phase 1 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
H3 Biomedicine
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H45N3O6
|
|||
| Canonical SMILES |
CC1C=CC(C(CCC(CC(=O)OC1C(=CC=CC(C)C2=CC=CC=N2)C)O)(C)O)OC(=O)N3CCN(CC3)C
|
|||
| InChI |
1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1
|
|||
| InChIKey |
YOIQWBAHJZGRFW-WVRLKXNASA-N
|
|||
| CAS Number |
CAS 1825302-42-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SF3b complex (SF3b) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02841540) A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of H3 Biomedicine. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.